论文部分内容阅读
目的：观察缓释二氢奎尼丁血药浓度与ＱＴｃ间期、ＱＴ间期离散度、ＱＵｃ间期等参数的相关性。方法：４０例心房颤动病人口服缓释二氢奎尼丁。心电图记录采用５０ｍｍ／ｓ纸速，２倍电压的方法。血药浓度测定采用ＴＤＸ方法。结果：①缓释二氢奎尼丁疗效明显，转复窦性心律５４．６％（６／１１例），预防心房颤动复发有效率７１．４％（２５／３５例）。②血药浓度与ＱＵｃ间期高度相关（ｒ＝０．９３，Ｐ＜０．０１）。③服药前、后心肌复极离散度比较无差异。用药后Ｕ波发生率明显增加，但未见药物的致心律失常作用。结论：缓释二氢奎尼丁血药浓度与ＱＵｃ间期高度相关。
OBJECTIVE: To observe the correlation between the release of dihydroquinidine and QTc interval, QT interval dispersion, QUc interval and other parameters. Methods: 40 patients with atrial fibrillation oral sustained release of dihydroquinidine. ECG recording using 50mm / s paper speed, 2 times the voltage method. Blood concentration determination using TDX method. Results: (1) The slow release of dihydroquinidine markedly improved the recovery of sinus rhythm (54.6%, 6/11 cases) and the prevention of recurrent atrial fibrillation (71.4%, 25/35). ② plasma concentration and QUc interval highly correlated (r = 0.93, P <0.01). ③ medication before and after the myocardial repolarization dispersion no difference. U wave incidence after treatment increased significantly, but no drug induced arrhythmia. CONCLUSIONS: The sustained-release dihydroquinidine serum concentration is highly correlated with the QUc interval.